康德萊醫械(01501.HK):上海翰凌股本增至6121萬元 懷格瑛泰及柯偉分別認購其3.8%及1.2%擴大後股權
格隆匯7月29日丨康德萊醫械(01501.HK)發佈公吿,於2021年7月29日,公司與懷格瑛泰、柯偉先生及上海翰凌餘下現有股東訂立增資協議,據此,上海翰凌的股本將由人民幣5815萬元增至人民幣6121萬元,懷格瑛泰及柯偉先生分別以代價人民幣3800萬元及人民幣1200萬元認購上海翰凌3.80%及約1.20%擴大後的股權。
待第二次增資及第二次股權認購事項完成後,公司於上海翰凌的股權將由約59.33%降至約56.36%。上海翰凌仍將為公司的非全資子公司。
上海翰凌致力於心臟瓣膜相關產品的研究及開發,其管線產品包括經導管主動脈瓣膜系統、可擴張血管鞘系統及自定位瓣膜擴張球囊導管。於本公吿日期,上海翰凌並無可識別收入流。
上海翰凌的第二次增資及第二次股權認購事項將提供額外的資金,以支持正在進行及潛在的研發項目,包括研發成本、材料、設備、人力資源、臨牀試驗、檢驗、註冊及取樣等成本及開支。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.